BRIEF-Clovis Oncology says Ariel3 study successfully achieved primary endpoint
September 07, 2017 at 18:18 PM EDT
* Clovis oncology presents comprehensive dataset from successful phase 3 Ariel3 maintenance treatment trial of Rucaparib in advanced ovarian cancer at ESMO 2017